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Abstract
Previously, the lower generation (DAB 8–generation 2 and DAB 16–generation 3) polypropylenimine dendrimers have been
shown to be effective gene delivery systems in vitro. In the current work, we sought to: (a) test the effect of the strength of the
carrier, DNA electrostatic interaction on gene transfer and (b) to study the in vivo gene transfer activity of these low molecular
weight (b1687 Da) non-amphiphilic plain and quaternary ammonium gene carriers. Towards this aim, methyl quaternary
ammonium derivatives of DAB 4 (generation 1), DAB 8, DAB 16 and DAB 32 (generation 4) were synthesised to give Q4, Q8,
Q16 and Q32, respectively. Quaternisation of DAB 8 proved to be critical in improving DNA binding, as evidenced by data from
the ethidium bromide exclusion assay and dendrimer–DNA colloidal stability data. This improved colloidal stability had a major
effect on vector tolerability, as Q8–DNA formulations were well tolerated on intravenous injection while a similar DAB 8–DNA
dose was lethally toxic by the same route. Quaternisation also improved the in vitro cell biocompatibility of DAB 16–DNA and
DAB 32–DNA dendrimer complexes by about 4-fold but not that of the lower generation DAB 4–DNA and DAB 8–DNA
formulations.
In contrast to previous reports with non-viral gene delivery systems, the intravenous administration of DAB 16–DNA and
Q8–DNA formulations resulted in liver targeted gene expression as opposed to the lung targeted gene expression obtained with
the control polymer-Exgen 500 [linear poly(ethylenimine)] and a lung avoidance hypothesis is postulated. We conclude that the
polypropylenimine dendrimers are promising gene delivery systems which may be used to target the liver and avoid the lung
and also that molecular modifications conferring colloidal stability on gene delivery formulations have a profound effect on
their tolerability on intravenous administration.
D 2004 Elsevier B.V. All rights reserved.
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1. Introduction
Advances in gene therapy are only ever likely to
make a clinical impact once effective gene delivery
systems are developed. Our focus is on the develop-
ment of synthetic gene delivery systems [1,2] as there
is still some uncertainty as to the safety of some of the
viral gene delivery systems [3,4]. While most efforts
aimed at preparing synthetic gene delivery systems
are focused on the use of amphiphilic [5] or polymeric
[6] cations, we have previously established that the
lower generation (generation 2–DAB 8 and generation
3–DAB 16) amine rich polypropylenimine dendrimers
are effective gene transfer systems in vitro [7] and
provided the first evidence that a relatively low
molecular weight (DAB 8, MW=773) non-amphi-
philic compound may be used for in vitro gene
transfer. Prior to our work, relatively poor gene
transfer activity had been reported with the higher
generation DAB 32 (generation 4), DAB 64 (gen-
eration 5) and DAB 128 (generation 6) dendrimers
[8,9]. Other groups working on the structurally related
polyamidoamine dendrimers, in which a combination
of amine and amide bonds are used to build up the
dendrimer, have found gene transfer activity to only
reside within the higher generation materials
(Ngeneration 7, MW G7 polyamidoamine den-
drimer=87, 000) with the lower generation materials
showing diminished activity [10]. The current work
describes the evaluation of the polypropylenimine
dendrimers and their quaternary amine derivatives as
in vivo gene delivery systems and reports on the
intrinsic ability of these dendrimers to distribute gene
expression preferentially to the liver rather than the
lung after intravenous injection. It is important to
systemically deliver genes to specific organs and most
other synthetic gene carriers devoid of homing ligands
(e.g. galactose) do not target the liver, a major site of
protein production.
2. Materials and methods
2.1. Synthesis and characterisation of quaternary
ammonium dendrimers
Polypropylenimine dendrimers (DABs, 500 mg,
Sigma-Aldrich, UK) were reacted in N-methylpyrro-
lidone (50 mL, Sigma-Aldrich) with methyl iodide (3
g, Sigma-Aldrich) in the presence of sodium iodide
(150 mg, Sigma-Aldrich) and under a stream of
nitrogen for 3 h (Scheme 1). The products were
recovered as yellow solids by precipitation in diethyl
ether, washing with absolute ethanol, passage over an
amberlite ion exchange column as described previ-
ously [11] and lyophilisation. Products were charac-
terised using elemental analysis (Perkin Elmer 2400
analyser) and 1H NMR in D20 (Bruker 400 MHz
spectrometer). The yields of Q4, Q8, Q16 and Q32
were 324, 331, 387 and 364 mg, respectively.
Scheme 1. The synthesis of quaternary ammonium dendrimers (Q4, Q8, Q16 and Q32 from DAB 4, DAB 8, DAB 16 and DAB 32,
respectively) as exemplified by the synthesis of Q8.
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2.2. DNA binding
DNA binding was measured by mixing appropriate
volumes and concentrations of 5% w/v dextrose
solutions of dendrimer and DNA. Size and zeta
potential of DNA formulations containing 100 Ag
mL1 DNA were analysed on a Malvern Zetasizer
3000HS and the exclusion of ethidium bromide
monitored by the reduced fluorescence assay [1]. A
90% reduction in the fluorescence of ethidium bromide
was termed complete DNA binding in this work.
For atomic force microscopy imaging samples (30
AL) were imaged by placing on to freshly cleaved
Muscovite mica and using Tapping Mode (TM)
Atomic Force Microscopy on Veeco Nanoscope (IIIa)
operating with an E type scanner in liquid with NP-S
tip. Scan rates of between 3 and 5Hzwere used and tip–
sample interactions minimised. Scale bars=100 nm.
2.3. Cytotoxicity
Cytotoxicity was assayed against a human epider-
moid cancer cell line (A431, ATCC CRL-1555) using a
previously publishedmethod [7] inwhich cells are seed-
ed at a density of 5000 cells per well in 96 well plates
and cells then exposed to 100 AL of dendrimer or den-
drimer/DNA formulations at various concentrations.
2.4. In vitro gene transfer
In vitro gene transfer ability against the A431 cell
line was evaluated relative to the efficient cationic lipid
DOTAP {(N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-tri-
methyl-ammonium methyl sulphate} that has been
used in clinical trials [12]. In vitro transfection of the
quaternary ammonium polypropylenimine dendrimers
was evaluated in the A431 cell line using a previously
published method in the absence of serum [7]. Cells
were seeded at a density of 104 cells per well in 96-
well plates. Dendrimer, DNAweight ratios were 10: 1
for DAB 4 and Q4; 5: 1 for DAB 8, Q8, DAB 16 and
DOTAP and 3: 1 for Q16, DAB 32 and Q32.
2.5. In vivo gene transfer
Groups of female Balb/C mice (n=5) were admin-
istered 50 Ag of the pCMV-h-galactosidase plasmid
(Invitrogen, UK) in a 200 AL volume via the tail vein
either as DAB 16, DNA (5:1); Exgen 500–DNA
(formulated according to the manufacturer’s instruc-
tions) or naked DNA.A further group ofmicewere also
administered a 200 AL volume of 5%w/v dextrose.
Mice were killed 24 h after injection and h-galactosi-
dase levels assayed as previously described [13].
In a separate experiment groups of female Balb/C
mice (n=4, meanFS.D.) were administered 100 Ag of
the pCMV-h-galactosidase plasmid in a 200 AL
volume via the tail vein either formulated as Q8,
DNA (5:1); Q16, DNA (3:1); DAB 32, DNA (3:1);
Q32, DNA (3:1); Exgen 500–DNA (formulated
according to the manufacturer’s instructions) or naked
DNA. A further group of mice were administered a 200
AL volume of 5%w/v dextrose. Mice were killed 24h
after injection and h-galactosidase levels assayed as
previously described [13].
In a separate experiment Female CD-1 nude mice
were administered 50 Ag DNA in a 200 AL volume
formulated as either DAB 16, DNA (5:1) or Exgen
500, DNA (formulated according to the manufactur-
er’s instructions). Livers were removed and fresh
tissues were incubated overnight at 37 8C in a solution
containing X-gal (1 mg/mL), in the presence of
potassium ferricyanide (5 mM) potassium hexacyano-
ferrate (5 mM) and magnesium chloride (2 mM).
Tissues were then fixed in a 10% formalin solution,
before being paraffin embedded, sectioned (20 Am
sections) and counterstained with eosin. The sections
were then imaged at a magnification of X63 by means
of light microscopy using Zeiss lens and Zeiss
Axioskop microscope. Image recording was carried
out using a colour CCD camera (Axiocam Camera
System) and AxioVision software (version 3.0.6).
2.6. Statistics
Statistics (ANOVA) were performed using Minitab
software.
3. Results
3.1. Synthesis and characterisation of quaternary
ammonium dendrimers
Quaternary ammonium dendrimers were synthes-
ised as shown in Scheme 1. The quaternary ammonium
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function was confirmed by the 13C NMR signal at a
chemical shift of d56.1, d56.0, d56.1 and d56.1, res-
pectively, for Q4, Q8, Q16 and Q32. 1H chemical shifts
were assigned as follows: (a) Q4—d1.69–2.35=N–
CH2–CH2–CH2–N and N–CH2–CH2–CH2–CH2–N,
d2.60=CH3–N, d2.71–2.79=–CH2–N, d3.06–
3.16=CH3–N
+, d3.48=–CH2–N
+; (b) Q8–d1.97–
2.35=N–CH2–CH2–CH2–N and N–CH2–CH2–CH2–
CH2–N, d2.71–2.75=CH2–N, d2.90=CH3–N, d3.07–
3.22=CH3–N
+; d3.35–3.56=–CH2–N
+; (c) Q16–
d1.60–2.30=N–CH2–CH2–CH2–N and N–CH2–
CH2–CH2–CH2–N, d2.74=–CH2–N; d2.83=CH3–N,
d3.01–3.31=CH3–N
+ and –CH2–N
+; d3.35–3.65=–
CH2–N
+; d) Q32–d1.80–2.31=N–CH2–CH2–CH2–N
and N–CH2–CH2–CH2–CH2–N, d2.34=CH2–N,
d2.60–2.70=CH2–N, d3.00–3.20=CH3–N
+; d3.41–
3.70=–CH2–N
+. The elemental analysis data were
used to calculate the % of amines that had been
converted to quaternary amines, i.e. 59.3%, 34.7%,
52.9% and 70.5% in Q4, Q8, Q16 and Q32, respec-
tively. This calculation only gives a crude measure of
the level of quaternary amine modification as the
presence of tertiary amines is evident in the 13C NMR
spectra of Q4 (d32.1 and d36.7); Q8 (d33.5 and d35.7),
Q16 (d35.1) and Q32 (d33.5). The overall level of
tertiary amines, as detected by 1H NMR (d2.60=CH3–
N) was either very low (~5%) or not detectable by the
NMR methods used here.
3.2. Improved DNA–dendrimer binding
All the quaternary ammonium dendrimers are able
to bind and condense DNA to produce colloidal
dispersions with a positive zeta potential (Table 1).
The introduction of quaternary ammonium groups
improved the DNA binding of DAB 4 and DAB 8,
both inefficient DNA binders [7] as evidenced by the
90% reduction in ethidium bromide fluorescence
obtained with Q4 and Q8 at an N/P ratio of 45:1 and
5:1, respectively. Improved DNA binding with Q8 is
further confirmed by the atomic force microscopy
images (Fig. 1) which show a more compact binding
arrangement in the Q8–DNA complexes when com-
pared to the DAB 8–DNA complexes.
3.3. Cytotoxicity
Complexation of the quaternary ammonium den-
drimers with DNA improved their biocompatibility,
increasing the IC50 values by between 3- and 10-fold
(Table 1). The incorporation of quaternary ammonium
groups improves the biocompatibility of the third and
fourth generation dendrimer, DNA complexes, when
compared to the plain dendrimer, DNA complexes
(Table 1). While the incorporation of quaternary
ammonium groups does not affect the cytotoxicity
of the lower generation dendrimer, DNA formulations
(Table 1); it should be noted that the incorporation of
quaternary ammonium groups increased the cytotox-
icity of DAB 8 (in the absence of DNA). IC50 values
of the higher generation dendrimer, DNA complexes
were increased by about 4–5-fold (Table 1) on
methylation of the dendrimers.
Although both Q32, DNA and DAB 32, DNA
formulations contained a dendrimer, DNA weight
ratio of 3:1, with the DAB 16 formulations there
Table 1
DNA binding and IC50 data on the quaternary ammonium dendrimer–DNA complexes
Dendrimer–DNA
formulation
Particle
size
(nm)a
Zeta potential
(mV, meanFS.D.
n=3)
Minimum dendrimer,
DNA weight ratio for
complete DNA binding
using the ethidium bromide
exclusion assay (N/P ratiob)
IC50 (IC50 of
quaternary ammonium
dendrimer in the absence
of DNA) (Ag mL1)
IC50 of plain dendrimer,
DNA formulations (IC50
of plain dendrimer in the
absence of DNA) data
from reference 7 (Ag mL1)
Q4, DNA (5:1 g g1) n.d.c +9.3F0.3 10: 1 (45: 1) N1000 (~100) 800 (220)
Q8, DNA (5:1 g g1) 144 +30.2F1.5 1: 1 (5: 1) ~350 (49) 669 (352)
Q16, DNA (5:1 g g1) 259 +31.5F4.1 0.5: 1 (2: 1) 129d (45) 36 (39)
Q32, DNA (3:1 g g1) 300 +28.8F7.5 1: 1 (4: 1) 33 (11) 5.7 (5.7)
a z-average mean of size distribution (average of three measurements).
b Nitrogen (dendrimer)/phosphate (DNA) ratio.
c A clear solution was obtained with this formulation.
d Dendrimer, DNA ratio=3:1 for the IC50 data only.
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was less of the dendrimer in the Q16 formulation as
dendrimer, DNA ratios were 3:1 and 5:1 for the Q16–
DNA and DAB 16–DNA formulations, respectively.
These dendrimer, DNA weight ratios were the
optimum ratios obtained from the in vitro transfection
experiment data (transfection data with less than
optimum dendrimer, DNA ratios are not shown).
The higher IC50 value recorded for the Q16–DNA
formulation may have been the result of this differ-
ence in dendrimer content.
An examination of the IC50 values for the uncom-
plexed plain and quaternary ammonium dendrimers
(Table 1) reveals that with the notable exception of
DAB 8, quaternisation has a minimal effect on the
biocompatibility of the plain dendrimers although there
are biocompatibility improvements seen with the
generations 3 and 4 dendrimer, DNA complexes.
3.4. In vitro transfection
In vitro transfection data (Fig. 2) reveal that with
DAB 16, quaternisation is capable of improving
transfection efficacy when high doses of the den-
drimer are applied to cells, and the same modification
has only a modest effect on transfection efficacy in the
case of DAB 32. Whereas with DAB 8, which usually
produces the best transfection in vitro in our hands
[7], quaternisation, despite the improvements in DNA
binding (Table 1), hampers the in vitro transfection
efficacy of this compound. An in depth examination
of transfection with DAB 16 and Q16 (Fig. 2) reveals
that as the concentration of dendrimer applied to the
cells diminishes the transfection efficacy increases
with DAB 16 and diminishes with Q16, indicating
that the superior cytotoxicity profile of the latter
complex favours gene transfer when higher doses of
DNA are applied and also that the intrinsic gene
transfer ability of Q16 is inferior to that of DAB 16.
This last conclusion stems from the fact that at lower
doses of DNA and hence lower doses of the
dendrimers, DAB 16 is a superior transfectant to
Q16 (Fig. 2).
3.5. In vivo transfection
The intravenous administration of DAB 16 pro-
duced statistically significantly higher liver levels of
gene expression (an over 100% increase) than was
found with DAB 16 in the lung and than was found
with Exgen 500 the linear polyethylenimine formula-
tion in the liver (Fig. 3a). Exgen 500 demonstrated a
typical pattern of gene expression in the lung after
intravenous administration [14]. Using the qualitative
X-gal staining assay, gene expression was also found
to be widespread in the liver with no areas of localised
gene expression, although the exact liver cell types
transfected was not clear from our assay due to the
tissue processing technique required for the X-gal
staining assay, i.e. incubation of liver slices at 37 8C
for 24 h (Fig. 3c). The CD1 strain of mouse was used
for this assay as the same experiment performed with
the Balb/C strain of mice produced reduced quality
Fig. 1. Representative atomic force micrographs shown in 3D format of (a) DAB 8, DNA (5:1) and (b) Q8, DNA (5:1), both dispersed in 5%w/v
dextrose. Scale bars=100 nm.
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histological samples at the end of the processing
period.
A 100 Ag dose of DNA formulated as DAB 8,
DNA (5:1) was found to be lethally toxic on
intravenous injection and caused embolism-like
(rapid) deaths. On the contrary Q8, DNA formulations
at the same dose, were well tolerated on intravenous
injection. The improved DNA binding exhibited by
Q8 (Fig. 1) when compared to DAB 8 and hence the
improved colloidal stability is thought to be the
genesis of this improved tolerability seen on quater-
nisation of the dendrimer. It is clear that the
biocompatibility improvements seen in vivo with
Q8, DNA formulations were not due to the improved
cytotoxicity of Q8, DNA formulations (Table 1) when
compared to DAB 8, DNA formulations.
A Q8, DNA (5:1) formulation of 100 Ag DNA
produced 64F30 mU g1 of h-galactosidase gene
expression in the liver and undetectable levels in the
lung (Fig. 3c). Similar DNA doses of Q16, DNA (3:1),
Q32, DNA (3:1) and DAB 32, DNA (3:1) all produced
less than 20 mU g1 of h-galactosidase gene expres-
sion in the liver and lung and interestingly while
transfection produced by Q16 was undetectable in the
lung, transfection produced by Q32 was undetectable
in the liver. A 100 Ag dose of Exgen 500, DNA
produced high lung levels of gene expression (Fig. 3c)
as has been reported by others [14].
Fig. 2. In vitro gene transfer ability against the A431 cell line of unmodified dendrimers (white bars) and quaternary ammonium dendrimers
(black bars). For the x-axis label, numbers in brackets represent the level of DNA added (Ag) to each well of a 96 well plate. n=4 and the Figure
is the depiction of one of a triplicate of experiments. a=Statistically significantly different ( pb0.05) from the plain unquaternised dendrimer,
b=statistically indistinguishable ( pN0.05) from DOTAP. Background data was obtained in the presence of 5% w/v dextrose. Dendrimer, DNA
weight ratios were 10:1 for DAB 4 and Q4; 5:1 for DAB 8, Q8, DAB 16 and DOTAP and 3:1 for Q16, DAB 32 and Q32.
Fig. 3. (A) In vivo gene expression after the intravenous injection of 50 Ag of the pCMV-h-galactosidase plasmid in a 200 AL volume to female
Balb/C mice (n=5, meanFS.D.). Groups were administered DAB 16, DNA (5:1); Exgen 500–DNA (formulated according to the manufacturer’s
instructions); naked DNA and 5%w/v dextrose *= statistically significantly superior to all other organs (pb0.05). (B) Liver micrographs from
female CD-1 nude mice 24 h after the intravenous injection of 50 Ag DNA in a 200 AL volume. DNAwas formulated as (a) DAB 16, DNA (5:1)
and (b) Exgen 500, DNA (formulated according to the manufacturer’s instructions). h-Galactosidase expression is shown by the blue X-gal
staining in the livers of mice injected with the DAB 16 formulation (a). Background staining is seen in the livers of mice injected with the Exgen
500 formulation (b). (C) In vivo gene expression after the intravenous injection of 100 Ag of the pCMV-h-galactosidase plasmid (Invitrogen,
UK) in a 200 AL volume to female Balb/C mice (n=4, meanFS.D.). Groups were administered Q8, DNA (5:1), Q16, DNA (3:1), DAB 32,
DNA (3:1), Q32, DNA (3:1), Exgen 500–DNA (formulated according to the manufacturer’s instructions), naked DNA and 5%w/v dextrose.
Mice were killed 24 h after injection and h-galactosidase levels assayed as previously described [13]. a=Statistically significant difference in
liver gene expression relative to 5% glucose, DNA, DAB 32 and Q32 ( pb0.05). b=Statistically significant difference in lung gene expression
relative to all treatment groups ( pb0.05).
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4. Discussion
The current study shows for the first time that gene
delivery with polypropylenimine dendrimers results in
gene expression occurring predominantly in the liver
(Fig. 3) as opposed to the lung, an attribute which
makes these gene carriers ideally suited for the
delivery of genes to the liver, when lung expression
is to be avoided such as in the delivery of anti-cancer
apoptosis causing genes or any other forms of suicide
gene therapy [15]. The liver is an important site for
protein synthesis and so an ability to target gene
A.G. Schatzlein et al. / Journal of Controlled Release 101 (2005) 247–258 253
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expression to the liver has profound therapeutic
implications. Issues that are critical to the activity of
these gene transfer agents include dendrimer size and
dendrimer surface functional groups. This is also the
first report of a low molecular weight non-amphiphilic
amine acting as a systemic gene delivery system.
It is clear that a quaternary ammonium surface
improves DNA binding, conferring DNA binding on
previously inefficient DNA binders—DAB 4 and
DAB 8 (Table 1, Fig. 1). The pKa of the polypropy-
lenimine dendrimer primary amines is 9.8 [16]. At the
neutral pH of study used in the current work, such
dendrimers will be ~99% ionised at equilibrium with
the ionised specie available for binding with phosphate
anions. However, at equilibrium there is still sufficient
charge mobility to prevent DNA binding by DAB 4
and DAB 8 and complete (90% reduction in fluo-
rescence) ethidium bromide exclusion is not observed
[7]. The addition of a permanent positive charge, by
enhancing charge separation within the molecule,
however, does cause the Q4 molecules to bind to the
DNA molecule forming a positively charged layer
which effectively electrostatically repels the approach
of ethidium bromide. From our earlier studies we also
know that DNA binding into colloidal particles is
enhanced by the ability of the dendrimer molecule to
bind to more than one phosphate group simultaneously
[7], and although Q4 is bound to DNA the small size of
Q4, relative to the spacing of the phosphate groups on
DNA, prevents the co-operative binding of more than
one phosphate group by a single molecule of Q4, thus
preventing the eventual collapse of the DNA molecule
into colloidal particles (Table 1).
The conversion of DAB 8 into its quaternary
ammonium derivative improves the DNA binding also
(Table 1). AFM images show that the loose arrange-
ment of DNA and dendrimer in the complex is
converted to a compact arrangement (Fig. 1) with a
mean particle size of 144 nm (Table 1); the permanent
positive charge thus effectively allowing more DNA
sites to be bound by the dendrimer molecule (Fig. 1) at
a minimum nitrogen, phosphate ratio of 5:1 (Table 1).
A look at the number of moles of phosphate
associated with each mole of dendrimer when
complete binding has been achieved, i.e. 0.13, 2.7,
14 and 15, respectively, for Q4 (4 external amine
groups), Q8 (8 external amine groups), Q16 (16
external amine groups) and Q32 (32 external amine
groups), shows that Q16 is thus an optimum sized
dendrimer for DNA condensation and no additional
phosphate groups become associated with the den-
drimer on doubling of the dendrimer size. With one
mole of Q16, almost every external amine group is
bound to a DNA phosphate group. When these figures
are compared with those from the unmodified
dendrimers [7], i.e. 20 moles of phosphate associated
with each mole of DAB 16 and DAB 32 on complete
condensation, two things become apparent. Firstly it
appears that only the first shell of amines are involved
in DNA binding once the dendrimer is quaternised,
with the quaternisation resulting in a molecule which
resists the penetration of the dendrimer shell by the
DNA molecule. A study of DNA binding by the plain
dendrimers suggested that DNA may penetrate
beyond the outer shell of the dendrimer and be
engaged in binding with amines on the inner
dendrimer shell [7].
A slight increase in dendrimer–DNA complex size
with increase in dendrimer molecular weight is
observed when Q8, Q16 and Q32 are considered
(Table 1), which is in agreement with earlier findings.
These earlier findings demonstrated that the size of
polymeric nanoparticles [17] and polymeric vesicles
[18] increases with increases in polymer molecular
weight, due to a diminishing radius of curvature with
increase in molecular weight. It is interesting to see
that the relationship appears to hold true for den-
drimers also.
While it is acknowledged that DNA binding is
relevant to gene transfer, the relevance of the subtle-
ties of the dendrimer, DNA binding discussed here are
not immediately apparent but become clearer on
closer examination of the data. Fig. 2 shows that this
improved DNA carriage by Q4 and Q8 is not
important at the cellular level and indeed is actually
detrimental to gene transfer, as exemplified clearly by
the data for Q8 (Fig. 2). The IC50s of DAB 4–DNA
complexes (800 Ag mL1) and DAB 8–DNA com-
plexes (669 Ag mL1) [7] are not much changed
(IC50 at least doubled or halved) by quaternisation
(Table 1) and hence alterations in the intrinsic toxicity
of the dendrimer–DNA complexes are not responsible
for the poorer transfection ability seen with Q8 when
compared to DAB 8 (Fig. 2). However, in vivo DAB
8 is acutely toxic due to poor DNA binding and the
resultant colloidal instability. The injection of DAB 8–
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DNA dendrimer complexes results in apparent (rapid)
embolism induced fatalities, whereas Q8, due to its
superior DNA binding (Fig. 1) and colloidal stability,
is well tolerated in mice and leads to high levels of
liver gene expression (Fig. 3c). We have thus tested
the electrostatic interaction hypothesis as set out
above, so much as it applies to polypropylenimine
dendrimers and proved that carrier, DNA electrostatic
charge interactions have a profound effect on gene–
dendrimer complex tolerability in vivo, as exemplified
using DAB 8 and Q8.
With Q16 the true effect of quaternisation at the
cellular level may be seen (Fig. 2). There is a
quadrupling of the IC50 of the dendrimer–DNA
complexes on quaternisation (Table 1) and an
improvement in gene transfer at high levels of DNA
(due to a decrease in complex cytotoxicity). However,
quaternisation effectively hampers gene transfer in
vitro (Fig. 2) as at low levels of DNA, DAB 16 is
superior to Q16 in vitro. Other workers have also
found that improving DNA binding by converting
amines to ammonium groups [19,20] actually reduced
gene transfer. We can conclude that at the cellular
level (in vitro) quaternisation only improves gene
transfer if it diminishes the cell cytotoxicity of the
complex (e.g. compare DAB 16 with Q16, Fig. 2,
Table 1). Also at the level of the entire organism (in
vivo) quaternisation is a powerful tool for improving
colloidal stability, improving gene-carrier complex
tolerability and thus enabling gene transfer in vivo
(Fig. 3c).
At the cellular level the increase in DNA binding
on conversion to quaternary ammonium molecules
may even hamper gene transfer by preventing the
release of DNA to the transcription machinery. The
release of DNA from gene carriers appears to be a
prerequisite for transcription [21]. Additionally, the
quaternary amines, by their very nature, are incapable
of buffering the cell contents and thus do not exploit
the usual buffering effects of primary amines in
facilitating gene transfer. This is important when it
is considered that polyamidoamine dendrimers [22]
and polyethylenimines [23] are said to improve gene
transfer by buffering the acidic intracellular vacuoles
and facilitating endosomal escape of DNA.
Our previous communication presented first time
evidence of the gene transfer activity of the lower
generation polypropylenimine dendrimers to cells in
culture [7] and recent work has shown that these
dendrimers are capable of oligonucleotide transfer to
live mammalian cells [24]. Other groups have
demonstrated gene transfer capabilities when propy-
lenimine type head groups are included in liposomal
formulations [25] and psueudorotaxane terminated
polypropylenimine dendrimers have been reported to
transfer genes to live mammalian cells [26].
Here we present, for the first time, evidence that
polypropylenimine dendrimers are capable of in vivo
gene transfer (Fig. 3). DAB 8 was found to be too
toxic for use via the intravenous route while all other
dendrimer formulations were well tolerated on intra-
venous administration.
With DAB 16, liver gene transfer was seen
predominantly, when compared to other organs (Fig.
3). Particulates on intravenous injection have been
known to accumulate in the liver and spleen [27] due
to their removal by macrophages. Surface modifica-
tion of such particulates with hydrophilic polymers
prevents this liver uptake by macrophages [28].
However, particulate cationic gene transfer agents
are usually reported to preferentially transfer genes to
the lung tissue [5,14,29,30] probably due to particle
aggregation and accumulation in the small lung
capillaries [31] since interventions which diminish
particle aggregation tend to divert gene expression
away from the lung [32]. However, the influence of
tissue specific factors on DNA uptake by certain
tissues [33,34] cannot be ruled out.
It must be concluded that polypropylenimine
dendrimer–DNA formulations unlike most cationic
gene transfer particles [5,14,30] avoid the lung as
other groups have recorded liver targeting of magnetic
resonance contrast agents bound to soluble polypro-
pylenimine dendrimers [35] and the intravenous
injection of neutral particles results in liver uptake
[27] predominantly by the Kupffer cells. A lung
avoidance hypothesis for gene expression with poly-
propylenimine dendrimers is thus proposed. It is
possible that the small size and non-amphiphilic
nature of these molecules allows the dendrimer–
DNA complexes to resist extreme particle aggregation
in vivo and eventual accumulation within the lung
capillaries. Aggregation of particulates will be pro-
moted by the association of polymer chains due to
chain entanglement of charge neutralised sections of
the polymer (charge neutralised by DNA or blood
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components) or alternatively facilitated by the hydro-
phobic associations of liposomal amphiphile hydro-
phobic groups.
The influence of the size of the dendrimers on
organ gene expression, is indicated by the fact that
between the generation 3 and 4 dendrimer there
appears to be a cross over of organs preferentially
transfected and while both Q16 and Q32 produced
low levels of organ transfection (b20 mU g1 h-
galactosidase), gene transfer with Q8 and Q16 was
undetectable in the lung, but detectable in the liver
and gene transfer with Q32 was undetectable in the
liver, but detectable in the lung. The level of gene
transfer obtained with DAB 32 was similar (3–6 mU
g1 h-galactosidase) in both organs.
Q16, despite an improvement in the cytotoxicity
(Table 1), which led to this agent showing improved
in vitro activity with higher DNA doses (Fig. 2), is not
an effective gene transfer agent in vivo. It is
conceivable that low local DNA concentrations and
hence low local dendrimer concentrations are
involved in gene transfer in vivo.
The exact cell type to which DAB 16 gene
expression is confined in the liver is not clear (Fig.
3b). The lack of splenic gene expression is not
indicative of the non-involvement of the reticuloen-
dothelial system generally and liver Kupffer cells
specifically in uptake as the precise link between gene
expression and particle uptake is poorly understood.
Cationic liposomes, for example, are also said to
distribute to the liver by Kupffer cell uptake [36]
although gene expression is predominantly seen in the
lung [5]. The identification of the liver cells trans-
fected in vivo will be the subject of future inves-
tigations as will the use of therapeutic genes to
achieve a pharmacodynamic response.
A number of studies have looked at the in vitro use
of polyamidoamine [22] and amphipathic [37] den-
drimers for gene delivery and recently polyamido-
amine dendrimers have been used to deliver genes
intratumourally [38] Additionally, polyamidoamine
dendrimer (generation 3–MW=6909)–cyclodextrin
conjugates have been shown to result in gene transfer
to the liver, lung, kidney and spleen [39] with spleen
levels being an order of magnitude higher than other
organs 12 h after dosing and the kidneys showing the
greatest level of gene transfer 24 h after dosing.
However, this is the first time that polypropylenimine
dendrimers have been used for in vivo gene delivery
and the first time that significantly higher levels of
liver gene expression have been observed on intra-
venous administration of non-viral gene formulations
which act by an intrinsic targeting ability without the
need for targeting ligands or charge shielding groups.
This observation may be exploited for the targeted
delivery of genes in the treatment of liver diseases,
especially where high lung levels of gene expression
are unwanted such as for the delivery of apoptosis
causing genes in the treatment of liver cancers.
5. Conclusions
In summary, polypropylenimine dendrimers and
their quaternary ammonium derivatives have been
tested in vivo as gene delivery systems. The gen-
eration 2 quaternary ammonium dendrimer (Q8) and
generation 3 plain dendrimer (DAB 16) were found to
target gene expression preferentially to the liver.
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